Adult-onset opsoclonus-myoclonus-ataxia syndrome as a manifestation of brazilian lyme disease-like syndrome: a case report and review of literature

Autopsy And Case Reports

Endereço:
Av. Prof. Lineu Prestes, 2565
São Paulo / SP
05508-000
Site: http://www.autopsyandcasereports.org
Telefone: (11) 3091-9448
ISSN: 22361960
Editor Chefe: Maria Claudia Nogueira Zerbini
Início Publicação: 28/02/2011
Periodicidade: Trimestral
Área de Estudo: Medicina

Adult-onset opsoclonus-myoclonus-ataxia syndrome as a manifestation of brazilian lyme disease-like syndrome: a case report and review of literature

Ano: 2014 | Volume: 4 | Número: 1
Autores: A. M. M. Lino, R. R. Spera, F. P. F. Campos, C. H. A. Freitas, M. R. T. Garcia, L. C. Lopes, A. S. Prokopowitsch
Autor Correspondente: A. M. M. Lino | [email protected]

Palavras-chave: opsoclonus-myoclonus syndrome, lyme neuroborreliosis, borrelia burgdorferi

Resumos Cadastrados

Resumo Inglês:

Described in 1962, the opsoclonus-myoclonus-ataxia syndrome (OMAS) is a rare, neurologically debilitating disorder with distinct characteristics that may begin in childhood or adult life. Although many cases remain without etiological diagnosis, others are related to neoplasms and infectious diseases. We report a 41-year-old previously healthy male with an 8-day history of headache, vertigo, nausea, vomiting, and nystagmus. After a normal brain computed tomography and lymphocytic pleocytosis in cerebral spinal fluid (CSF), intravenous acyclovir therapy was initiated in the emergency room.
On the third day of hospitalization, the diagnosis of OMAS was made based on the presence of chaotic and irregular eye movements, dysarthric speech, gait instability, generalized tremor, and myoclonic jerks. In the face of his neurological worsening, ampicillin followed by nonspecific immunotherapy
(methylprednisolone and intravenous immunoglobulin) was prescribed, with mild clinical improvement. After a thorough laboratory workup, the definite diagnosis of neuroborreliosis was established and ceftriaxone (4 g/daily/3 wks) and doxycycline (200 mg/day/2 mo) was administered. Toward the end
of the ceftriaxone regimen, the neurologic signs substantially improved. We believe this to be the first case description of OMAS as clinical presentation of Brazilian Lyme disease-like syndrome (Baggio-Yoshinari syndrome).